This finding is in good accordance with data for other solid tumours underinhibition of the EGFR pathway.23, 24Concerning RAS analysis, our results are consistent with those from previous studiesshowing that patients with mutant tumours are unlikely to benefit from anti-EGFRtherapy.25 The gene discussed is EGFR; the disease is neoplasm.